Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab plus ECX versus ECX alone in first-line metastatic esophago-gastric adenocarcinoma
2005-000146-36Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of matuzumab in Esophago-Gastric Adenocarcinoma and gastric adenocarcinoma (2 arms), sponsored by Merck KGaA. Primary endpoints: Tumor response rate, Tumor response assessment schedule during treatment and 1 more. Started Mar 2005; status: completed.
02
Drugs
matuzumab
03
Conditions
Esophago-Gastric Adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2005-000146-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000146-36.